Semi sales fell 9% and management is building new capacity for a recovery that keeps slipping.
Thesis: Merck is a pharma conglomerate with a semi-materials problem. Margins are collapsing under the weight of idle capacity and premature expansion costs. No AI leverage exists here. You are paying a healthcare multiple for a commoditized materials business in a cyclical trough.
Verdict: AVOID — Conviction: MEDIUM
Catalyst: H2 2024 industry recovery timing. If the materials cycle lags the logic recovery, Merck faces further margin dilution from fixed costs.
Key Risk: Prolonged semiconductor downturn. MSI expectations are down mid-teens and Merck has no way to decouple from wafer start volumes.
The Tell: CEO says trend lines are confirming the plan while margins dropped 640 basis points. They admitted to idle costs in the same breath as new site ramp-up costs. This is expansion into a demand vacuum.
Friction Level: MODERATE_FRICTION — Management claims Semiconductor Solutions is outperforming the market by only falling 9%. The bear thesis identifies this as decline without pricing power. High idle costs and premature expansion are destroying the margin floor.
Report not found
The report data is no longer available. Please return to the archive.